Browse our 650+ Publications​

Latest Publications

Prevalent and diverse intratumoral oncoprotein-specific CD8+ T cells within polyoma virus-driven Merkel cell carcinomas

Jing et al.
Cancer Immunology Research
March 2020
Authors and Affiliates
Lichen Jing 1, Mariliis Ott 1, Candice D. Church 2, Rima M. Kulikauskas 2, Dafina Ibrani 2, Jayasri G. Iyer 2, Olga K. Afanasiev 2, Aric Colunga 2, Maclean M. Cook 2, Hong Xie 6, Alexander L. Greninger 6, Kelly G. Paulson 8,3, Aude G. Chapuis 8,3, Shailender Bhatia 8,3, Paul Nghiem 2,3, David M. Koelle 1,4,5,6,7,9 1 Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA 2 Division of Dermatology, Department of Medicine, University of Washington, Seattle, WA, USA 3 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA 4 Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA 5 Department of Global Health, University of Washington, Seattle, WA, USA 6 Department of Laboratory Medicine, University of Washington, Seattle, WA, USA 7 Benaroya Research Institute, Seattle, WA, USA 8 Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA 9 Correspondence at: 750 Republican Street, Room E651, Seattle, WA, 98109, USA; tel 206 616 1940; fax 206 616 4898, email dkoelle@medicine.washington.edu

Peripheral T cell expansion predicts tumour infiltration and clinical response

Wu et al.
Nature
February 2020
Authors and Affiliates
Wu TD1, Madireddi S2, de Almeida PE2, Banchereau R3, Chen YJ4, Chitre AS2, Chiang EY2, Iftikhar H2, O'Gorman WE5, Au-Yeung A5, Takahashi C5, Goldstein LD6, Poon C7, Keerthivasan S2, de Almeida Nagata DE2, Du X2, Lee HM2, Banta KL2, Mariathasan S3, Das Thakur M8, Huseni MA8, Ballinger M8, Estay I8, Caplazi P9, Modrusan Z4, Delamarre L2, Mellman I2, Bourgon R6, Grogan JL10; 1 Department of Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, CA, USA. twu@gene.com. 2 Department of Cancer Immunology, Genentech, Inc., South San Francisco, CA, USA. 3 Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA. 4 Department of Microchemistry, Proteomics, Lipidomics and Next Generation Sequencing, Genentech, Inc., South San Francisco, CA, USA. 5 Department of OMNI Biomarker Development, Genentech, Inc., South San Francisco, CA, USA. 6 Department of Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, CA, USA. 7 Department of Research Biology, Genentech, Inc., South San Francisco, CA, USA. 8 Department of Development Sciences, Genentech, Inc., South San Francisco, CA, USA. 9 Department of Pathology, Genentech, Inc., South San Francisco, CA, USA. 10 ArsenalBio, South San Francisco, CA, USA. jane@arsenalbio.com.

Immuno-genomic landscape of osteosarcoma

Wu et al.
Nature Communications
February 2020
Authors and Affiliates
Wu CC1, Beird HC1, Andrew Livingston J2,3, Advani S3, Mitra A1, Cao S4, Reuben A5, Ingram D6, Wang WL6, Ju Z4, Hong Leung C7, Lin H7, Zheng Y1, Roszik J1, Wang W4, Patel S2, Benjamin RS2, Somaiah N2, Conley AP2, Mills GB8, Hwu P2, Gorlick R3, Lazar A6, Daw NC3, Lewis V9, Futreal PA10; 1 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2 Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3 Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4 Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5 Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 7 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 8 Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 9 Department of Orthopedic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 10 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. afutreal@mdanderson.org.

Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas

Aslan et al.
Nature Communications
February 2020
Authors and Affiliates
Aslan K1,2,3,4, Turco V1,2, Blobner J1,2, Sonner JK1,2,5, Liuzzi AR6, Núñez NG6, De Feo D6, Kickingereder P7, Fischer M7, Green E1,2, Sadik A8, Friedrich M1,2, Sanghvi K1,2,3, Kilian M1,2,3, Cichon F1,2,3, Wolf L1,2, Jähne K1,2, von Landenberg A1,2, Bunse L1,2, Sahm F9,10, Schrimpf D9,10, Meyer J9,10, Alexander A1,3,7, Brugnara G7, Röth R11, Pfleiderer K1,7, Niesler B11, von Deimling A9,10, Opitz C8, Breckwoldt MO1,7, Heiland S7, Bendszus M7, Wick W12,13,14, Becher B6, Platten M15,16,17; 1 DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 2 Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Heidelberg, Germany. 3 Faculty of Biosciences, Heidelberg University, Heidelberg, Germany. 4 Immatics Biotechnologies GmbH, Tübingen, Germany. 5 Institute of Neuroimmunology and Multiple Sclerosis, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 6 Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland. 7 Department of Neuroradiology, Heidelberg University Medical Center, Heidelberg, Germany. 8 Brain Cancer Metabolism Group, German Cancer Research Center (DKFZ), Heidelberg, Germany. 9 DKTK Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 10 Department of Neuropathology, Heidelberg University Medical Center, Heidelberg, Germany. 11 nCounter Core Facility, Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany. 12 Department of Neurology, Heidelberg University Medical Center, Heidelberg, Germany. 13 National Center for Tumor Diseases Heidelberg, DKTK, Heidelberg, Germany. 14 DKTK CCU Neurooncology, DKFZ, Heidelberg, Germany. 15 DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. m.platten@dkfz-heidelberg.de. 16 Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Heidelberg, Germany. m.platten@dkfz-heidelberg.de. 17 Helmholtz Institute for Tranlational Oncology (HI-TRON), Mainz, Germany. m.platten@dkfz-heidelberg.de.

T Cell Repertoire in Combination with T cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma

Farah et al.
Journal of Investigative Dermatology
February 2020
Authors and Affiliates
Maya Farah1,*, Alexandre Reuben2,*, Ivelina Spassova3, Richard K. Yang1, Linda Kubat3, Priyadharsini Nagarajan1, Jing Ning4, Wen Li4, Phyu P. Aung1, Jonathan L. Curry1,5,6, Carlos A. Torres-Cabala1,5, Courtney W. Hudgens6, Selma Ugurel7, Dirk Schadendorf7, Curtis Gumbs8, Latasha D. Little8, Andrew Futreal8, Ignacio I. Wistuba6, Victor G. Prieto1,5, Linghua Wang8, Michael K. Wong9, Jennifer A. Wargo8,10, Jürgen C. Becker3,7,11,, and Michael T. Tetzlaff1,6,; The University of Texas MD Anderson Cancer Center 1 Department of Pathology and Laboratory Medicine 2 Department of Thoracic/Head & Neck Medical Oncology 3Translational Skin Cancer Research, University Clinic Essen, Germany 4 Department of Biostatistics 5 Department of Dermatology 6 Department of Translational and Molecular Pathology 7 Department of Dermatology, University Clinic Essen, Germany 8 Department of Genomic Medicine 9 Department of Melanoma Medical Oncology 10Department of Surgical Oncology 11German Cancer Consortium (DKTK), German Cancer Center (DKFZ), Heidelberg, Germany

Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R- Dependent STING Activation by Tumor-Derived cGAMP

Zhou et al.
Immunity
February 2020
Authors and Affiliates
Yi Zhou,1,3 Mingjian Fei,1,3 Gu Zhang,1 Wei-Ching Liang,1 WeiYu Lin,1 Yan Wu,1 Robert Piskol,1 John Ridgway,1 Erin McNamara,1 Haochu Huang,1 Juan Zhang,1 Jaehak Oh,1 Jaina M. Patel,2 Diana Jakubiak,1 Jeff Lau,1 Beth Blackwood,1 Daniel D. Bravo,1 Yongchang Shi,1 Jianyong Wang,1 Hong-Ming Hu,2 Wyne P. Lee,1 Rajiv Jesudason,1 Dewakar Sangaraju,1 Zora Modrusan,1 Keith R. Anderson,1 Søren Warming,1 Merone Roose-Girma,1 and Minhong Yan1,4,* 1Genentech Inc., South San Francisco, CA, USA 2Cancer Immunobiology Laboratory, Earle A. Chiles Research Institute, Portland, OR, USA 3These authors contributed equally 4Lead Contact *Correspondence: minhong@gene.com

T-cell lymphoma secondary to checkpoint inhibitor therapy

Anand et al.
Journal for ImmunoTherapy of Cancer
February 2020
Authors and Affiliates
Anand K1, Ensor J2, Pingali SR3, Hwu P4,5, Duvic M4, Chiang S3, Miranda R4, Zu Y3, Iyer S6; 1 Houston Methodist Cancer Center, Houston, Texas, USA kartikanand88@gmail.com spiyer@mdanderson.org. 2 Houston Methodist Research Institute, Houston, Texas, USA. 3 Houston Methodist Cancer Center, Houston, Texas, USA. 4 University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 5 Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6 University of Texas MD Anderson Cancer Center, Houston, Texas, USA kartikanand88@gmail.com spiyer@mdanderson.org.

CD45RB Status of CD8+ T Cell Memory Defines T Cell Receptor Affinity and Persistence

Krummey et al.
Cell Reports
February 2020
Authors and Affiliates
Scott M. Krummey,1,2,7,* Anna B. Morris,1 Jesica R. Jacobs,3 Donald J. McGuire,4 Satomi Ando,4 Katherine P. Tong,1 Weiwen Zhang,1 Jennifer Robertson,1 Sara A. Guasch,1 Koichi Araki,4,6 Christian P. Larsen,1 Brian D. Evavold,3 Haydn T. Kissick,5 and Mandy L. Ford1 1Emory Transplant Center, Emory University School of Medicine, Atlanta, GA, USA 2Department of Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA 3Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA 4Department of Microbiology & Immunology, Emory University School of Medicine, Atlanta, GA, USA 5Department of Urology, Emory University School of Medicine, Atlanta, GA, USA 6Present address: Division of Infectious Diseases, Center for Inflammation and Tolerance, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA 7Lead Contact *Correspondence: skrumme@emory.edu https://doi.org/10.1016/j.celrep.2020.01.016

Immune awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy

Valpione et al.
Nature Cancer
February 2020
Authors and Affiliates
Valpione S1,2, Galvani E1, Tweedy J1, Mundra PA1, Banyard A3, Middlehurst P4, Barry J3, Mills S4, Salih Z2, Weightman J5, Gupta A2, Gremel G1, Baenke F1, Dhomen N1, Lorigan PC2, Marais R1; 1 Molecular Oncology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park SK10 4TG, United Kingdom. 2 The Christie NHS Foundation Trust, 550 Wilmslow Road, Manchester M20 4BX, United Kingdom. 3 Advanced Imaging and Flow Cytometry, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park SK10 4TG, United Kingdom. 4 Manchester Cancer Research Centre Biobank, The Christie NHS Foundation Trust, 550 Wilmslow Road, Manchester M20 4BX, United Kingdom. 5 Molecular Biology Core Facility, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park SK10 4TG, United Kingdom.

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

Sharma et al.
Nature Communications
January 2020
Authors and Affiliates
Sharma M1, Khong H1, Fa'ak F1, Bentebibel SE1, Janssen LME1, Chesson BC1, Creasy CA1, Forget MA1, Kahn LMS1, Pazdrak B1, Karki B1, Hailemichael Y1, Singh M1, Vianden C1, Vennam S2, Bharadwaj U3, Tweardy DJ3, Haymaker C1, Bernatchez C1, Huang S4,5, Rajapakshe K4, Coarfa C4, Hurwitz ME6, Sznol M7, Hwu P1, Hoch U2, Addepalli M2, Charych DH2, Zalevsky J2, Diab A1, Overwijk WW8,9,10,11; 1 Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2 Nektar Therapeutics, 455 Mission Bay Blvd South, San Francisco, CA, USA. 3 Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA. 4 Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA. 5 Dan L. Duncan Cancer Center, Houston, TX, USA. 6 Yale Comprehensive Cancer Center, New Haven, CT, USA. 7 Yale University Cancer Center, Yale University, New Haven, CT, USA. 8 Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. woverwijk@nektar.com. 9 Nektar Therapeutics, 455 Mission Bay Blvd South, San Francisco, CA, USA. woverwijk@nektar.com. 10 The University of Texas MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, Houston, TX, USA. woverwijk@nektar.com. 11 Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. woverwijk@nektar.com.
Previous Next